Travere Therapeutics, Inc.TVTXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-338.69M
↓ 177% below average
Average (9y)
$-122.26M
Historical baseline
Range
High:$-6.61M
Low:$-338.69M
CAGR
+52.5%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-338.69M | -5.3% |
| 2023 | $-321.61M | -49.8% |
| 2022 | $-214.66M | -451.2% |
| 2021 | $-38.94M | +76.0% |
| 2020 | $-162.59M | -120.4% |
| 2019 | $-73.78M | -65.2% |
| 2018 | $-44.66M | -576.0% |
| 2017 | $-6.61M | +51.1% |
| 2016 | $-13.52M | -78.3% |
| 2015 | $-7.58M | - |